Randomized, open-label, parallel-group, multi-centre phase II clinical trial of active cellular immunotherapy with preparation DCVAC/PCa in patients with castrate-resistant prostate cancer
Latest Information Update: 30 Aug 2023
Price :
$35 *
At a glance
- Drugs Stapuldencel-T (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 29 Apr 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2012 New trial record